Global Particle Therapy Market Report and Forecast 2024-2032

Global Particle Therapy Market Outlook

The global particle therapy market size was valued at USD 747.1 million in 2023, driven by increasing advancements and research studies to find better cancer treatment radiation therapies without damaging nearby tissues. The market size is anticipated to grow at a CAGR of 8.3% during the forecast period of 2024-2032 to achieve a value of USD 1531.1 million by 2032.

Particle Therapy: Introduction

Particle therapy, also known as particle beam therapy, is an advanced form of cancer treatment that uses charged particles such as protons or heavy ions to target and destroy cancer cells. Particle therapy delivers highly precise and controlled doses of radiation to tumours while minimizing damage to surrounding healthy tissues. Particle therapy is proven to show promising results in the treatment of certain cancers but it may not be considered for all types of cancer and patients.

Global Particle Therapy Market Analysis

The growth of the market is driven by increased research studies by scientists and doctors to provide better treatment options for cancer patients. For example, in a randomized clinical trial, researchers have discovered evidence promising shorter treatment time for breast cancer patients. In this trial, two separate dosing schedules of pencil-beam scanning proton therapy were compared. This therapy is known to be the most advanced type of proton therapy which is precise in targeting cancer cells without damaging healthy tissue resulting in reduced risk of side effects.

The particle therapy market demand is also driven by the increasing awareness among pharmaceutical companies that are looking to develop new and effective treatment therapy options for patients suffering from cancers and tumours all over the world. These companies are trying to develop proton therapies that are enabled with extreme precision when it comes to targeting cancer cells. For example, Terapet, a Geneva-based CERN start-up recently announced that they have ended up raising 2.3 million CHF (Swiss Francs) for the development of the next generation of nuclear imaging products. Terapet’s novel technology has the potential to make nuclear medicine imaging more accessible for every patient in the future. Terapet is targeted towards ensuring the right dose for every patient, every time. The company is also to exhibit its first product to the particle therapy community at PTCOG 2023 in Madrid.

The increased awareness and adoption of particle therapies are further escalating the global particle therapy market growth. For example, the inauguration of the much-awaited proton beam therapy facility in India took place earlier this year in Mumbai. This facility is the first in a public setup in the country. The government is set to provide this cutting-edge technology to 60% of the patients for free and the other 40% would pay a subsidized amount. The availability of such treatment options plays a huge role in reducing the mortality rate due to certain medical conditions such as cancer.

Additionally, Hitachi has successfully delivered a heavy ion therapy system to Taipei Veterans General Hospital situated in Taiwan and the system has also started operating as well.  This is the first-ever heavy ion therapy system delivery made by Hitachi, outside of Japan.

Hitachi is committed to enhancing the quality of life for cancer patients in Taiwan and promoting patient-centered treatment. The company will persist in its efforts to expand the global reach of its particle therapy system business, thereby advancing the field of minimally invasive cancer treatments. Having successfully treated more than 85,000 patients to date, Hitachi offers a range of high-performance products and services. These offerings range from the specialized compact Proton single-room solution to the versatile Hybrid System, which combines the capabilities of proton and carbon therapy to provide even greater value.

Global Particle Therapy Market Segmentations

Market Breakup by Therapy Type

• Proton Therapy

• Heavy Ion Therapy

• Fast-Neutron Therapy

Market Breakup by Cancer Type

• Prostate Cancer

• Breast Cancer

• Lung Cancer

• Head and Neck Cancer

• Other Cancers

Market Breakup by Applications

• Food and Beverage

• Nutraceuticals and Pharmaceuticals

• Cosmetics and Personal Care

Market Breakup by Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Global Particle Therapy Market Overview

The global market is experiencing a significant rise in adoption, awareness, and demand. This rising awareness has led to a surge in clinical studies aimed at discovering the full potential of particle therapy for cancer and tumour treatment. Moreover, the increasing reliability of this treatment method, backed by positive outcomes, has further bolstered its popularity contributing to the global particle therapy market growth. According to data from the American Cancer Society, the United States is expected to witness over 1.9 million new cancer cases in 2023, with cancer ranking as the second leading cause of death and projected to account for approximately 609,820 deaths, equivalent to 1,670 lives lost each day.

Geographically, North America is currently leading the regional market, and this dominance is expected to persist throughout the forecast period. Factors contributing to regional market dominance include the presence of a well-established healthcare system, a growing geriatric population, and a rising number of healthcare facilities offering proton therapy favorable reimbursement policies.

Global Particle Therapy Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Advanced Oncotherapy

• IBA Worldwide

• Accuray Incorporated

• Brainlab

• Elekta AB

• Panacea

• Shinva Medical Instrument Co. Ltd

• xstrahl

• Danfysik A/S

• Hitachi Ltd.

Key Highlights of the Report